DHTML Menu / JavaScript Menu Powered by Milonic
Home    |    Contact Us    |    Request Proposal     USAEU  
BASi
about
Follow BASi_news on Twitter

List of GLP Assays

BASi has developed over 1100 analytical methods. What you see below is only a partial list, those assays we can discuss publicly. The majority of assays we perform are confidential and proprietary. Our analytical expertise is much broader than this list may imply, and we are constantly developing additional methods. Be sure to ask if you dont see precisely what you want on this list.

Search by Test Article

Search is not case-sensitive. Example: mor would return Morphine and Oxymorphone.
This list is updated regularly. Watch for additions and changes.

Therapeutic Category:
Analgesic | Antidiabetic | Antibiotic | Antiviral | Biomarker | Cardiac | Gastric | Neurology/CNS | Oncology | Steroid

List of Cardiac Related GLP Assays

updated: 7/7/2010
Test Article Matrix Anticoagulant Assay Type LLOQ Isotope IS Method #
5-Hydroxypropafenone*  Human Plasma  Heparin  LC-MS/MS  1.00 ng/mL  Yes  LCMS17 
Acebutolol & Diacetolol*  Human Plasma  Heparin  LC-FL  10.0 ng/mL    LC27 
Amiodarone & Desethylamiodarone  Human Plasma  EDTA  LC-MS/MS  5.00 ng/mL  Yes  SAP.1285 
Atenolol*  Whole Blood  EDTA   LC-FL  20.0 ng/mL    LC5 
Bisoprolol*  Human Plasma  Heparin  LC-FL  0.500 ng/mL    LC7 
Diltiazem  Human Plasma  Heparin  LC-MS/MS  1.000 ng/mL  Yes  SAP.1309 
Diltiazem, Desaretyldiltiazem, & Desmethyldiltiazem*  Human Plasma  Heparin  LC-UV  5.00 ng/mL    LC28 
Dobutamine*  Human Plasma  Heparin  LC-EC  0.391 ng/mL    820-0154 
N-Despropylpropafenone*  Human Plasma  Heparin  LC-MS/MS  1.00 ng/mL  Yes  LCMS17 
Nifedipine*  Human Plasma  Heparin  LC-MS/MS  0.500 ng/mL    LCMS5 
Propafenone*  Human Plasma  Heparin  LC-MS/MS  1.00 ng/mL  Yes  LCMS17 
Quinidine*  Human Plasma  Not Specified  LC-UV  25.0 ng/mL    820-0156 
Quinidine*  Human Plasma  Heparin  LC-FL  20.0 ng/mL    LC31 

Highlighted items have validation in progress, or exploratory validation work has been completed.
*May require re-validation to current standards.
†May require third party approval for use of reference or internal standard.